Date: March 28, 2023

Source: The First Affiliated Hospital of JNU

Translators: LIN Xing, WU Jiayi

A team led by Profs. Zhao Jianfu, Yin Haiyan and Chen Tianfeng of the First Affiliated Hospital of JNU has reported significant progress in developing novel nanodrugs to reverse lung cancer radioresistance. The team has published its findings in the international journal Nano Today (IF=18.962) under the title Reversing lung cancer radioresistance by hyperpermeable tellurium nanotherapeutics via remodeling tumor microenvironment. The First Affiliated Hospital is the paper's first completing unit, with Zhao Fengzhi, an attending physician, as the first author; Huang Wei, a doctoral researcher, as co-first author; and Chief Physician Zhao, Yin and Chen as corresponding authors.

(Screenshot of the paper)

The team has focused on chemically innovative drug design and application of diagnosis and treatment, both based on clinical situations, through interdisciplinary integration. It has accumulated years of experience in numerous aspects, including targeted drug design on chemical characteristics of tumors, chemosensitization, radiosensitization and immunomodulation.

Its studies were funded by the National Science Fund for Distinguished Young Scholars, the General Program of the National Natural Science Foundation of China and the Guangdong Provincial Projects of Science and Technology.